NEWS RELEASE

CORDLIFE AND THOMSON MEDICAL LAUNCH THE FIRST UMBILICAL CORD TISSUE BANKING SERVICE IN SINGAPORE

- In line with Cordlife's growth plans to offer complementary services to its clients through partnerships and collaborations
- New offering will boost Cordlife's recurring income stream
- New service offers parents with an additional option for storing their children’s stem cells

Singapore, May 9, 2013 – Cordlife Group Limited (“Cordlife”, and together with its subsidiaries, the “Group”), a leading cord blood and tissue banking service provider, today announced the launch of a new umbilical cord tissue banking service in Singapore, in partnership with Thomson Medical Pte. Ltd. (“Thomson Medical”). The new offering, commencing on Mother’s Day on May 12, 2013, will be the first such service to be launched in Singapore.

Mr Jeremy Yee, Executive Director and Chief Executive Officer of Cordlife, said: “As an industry leader in newborn stem cell banking and the larger of only two cord blood banking service providers in Singapore, we are pleased to be the first to offer parents here the additional option of storing their children’s precious stem cells from cord tissue. Launching this new offering with our long-time esteemed partner, Thomson Medical, is in line with Cordlife’s plans to grow our business via complementary services and through partnerships and collaborations. This will boost our recurring income stream in the long run, and continue to enhance value for our shareholders.”

The initial public offering of Cordlife’s shares was sponsored by PrimePartners Corporate Finance Pte. Ltd., who assumes no responsibility for the contents of this news release.

Page 1 of 4
Ms. Alice Scott, President (Singapore) of Thomson Medical, said: “Thomson Medical has had a strong working relationship with Cordlife since its inception in 2001. As a healthcare service provider dedicated to quality care for mothers throughout their pregnancy and childbirth journey, we are always looking for ways to offer new and innovative services and products which will provide safe and better outcomes for mothers and their babies.

“We share Cordlife’s mission of offering an additional peace of mind for parents with best-in-class services, and are delighted to be invited to be the first hospital to offer Cordlife’s cord tissue collection service.”

Following the first two months from the launch, the service will also be available at other hospitals islandwide. Cordlife will be offering the new service through its wholly-owned subsidiary, Cordlife Technologies Pte. Ltd., which has the rights to use patented technology and expertise pertaining to umbilical cord tissue banking. Cordlife first launched the provision of cord tissue banking to clients in Hong Kong in March 2011 through the Group’s wholly-owned subsidiary, Cordlife (Hong Kong) Limited. Within a short span of time, the Group saw an increase in the number of parents opting for the service in Hong Kong. From July 2012 to December 2012, the number of new clients who signed up for the service increased 27.8%, compared to the same period in 2011.

Mr Yee said: “The good take-up rate for cord tissue storage services that we have experienced in Hong Kong demonstrated to us that parents often welcome the additional option of storing their children’s cord tissue, along with the cord blood, as the future implications can be manifold. This is because cord tissue is rich in two kinds of stem cells – one of which is not found in the cord blood, and the other only in small quantities. Storing the tissue provides additional treatment options, and therefore safeguards for the child, if he or she should ever need them.”
Cord blood is rich in hematopoietic stem cells, while cord tissue is rich in mesenchymal (MSCs) and epithelial (EpSCs) stem cells, which can potentially help with:

- The repair of injured tissues and organs and the treatment of various diseases (using MSCs); and
- The forming of soft tissues that connect, support or surround other structures and organs of the body including cornea, skin and liver (using EpSCs).

Funding for the initial cost of implementation of the new service will come from the net proceeds raised from the initial public offering (“IPO”) of the Group on the Singapore Exchange Securities Trading Limited. As disclosed in the Group’s prospectus dated March 21, 2012, the Group intends to use S$16,600,000 (representing approximately 55.9% of the IPO proceeds of the Group) for the purposes of developing and expanding the Group’s business and operations in Singapore and overseas.

The above utilisation is in accordance with the intended use of the proceeds from the IPO. The Group will make announcements via SGXNET when the proceeds of the Group’s IPO are materially disbursed.

The offering of the new services, when launched, are expected to contribute to the earnings of the Group commencing in the next financial year ending June 30, 2014.\(^1\)

\(^1\) Cordlife’s next financial year commences on July 1, 2013
ABOUT CORDLIFE GROUP LIMITED (Bloomberg stock code: CLGL)

Incorporated in May 2001, Cordlife Group Limited is an award-winning and established cord blood and tissue banking service provider. Amongst the first private cord blood banks in Asia, the Group has established a dominant market leader position in Singapore\(^2\). Today, it has the larger market share of the only two private cord blood banks in Singapore. In Hong Kong, it is amongst the three market leaders for private cord blood banks.

The Group collects, processes, tests, cryopreserves and stores stem cells from the umbilical cord blood of the child at birth, allowing customers to preserve their child’s cord blood stem cells for treatment later in his or her life if their child so requires. In March 2011, the Group launched umbilical cord tissue banking service in Hong Kong, offering an additional service that allows customers to collect and store their child’s umbilical cord tissue, which is a rich source of mesenchymal and epithelial stem cells and may potentially help repair the body in different ways.

Cordlife’s business model, which allows customers to opt for a one-time lump sum payment, or annual payments until the child reaches maturity (21 years old in Singapore and 18 years old in Hong Kong), provides the Group with a stable pool of recurring cash flow.

In addition, Cordlife, through its collaborative relationships or arrangements with major private hospitals and clinics such as Thomson Medical, Parkway East Hospital and Raffles Hospital, has continued to increase public awareness of its cord blood banking services in Singapore. Overseas, the Group has a 10% direct stake in China Cord Blood Corporation – a top operator in China holding majority shares in the Beijing, Guangdong and Zhejiang Cord Blood Banks, and an approximately 20% share in Shandong Cord Blood Bank.

\(^2\) According to the industry data in the Company’s prospectus dated March 21, 2012
Cordlife was amongst the first cord blood banks in Asia to be accredited by AABB (formerly known as the American Association of Blood Banks), an association involved in the field of transfusion medicine and cellular therapies. The Group is one of the first private cord blood banks in Singapore and amongst the first in Hong Kong to have released cord blood units for transplants and other therapeutic use. In Singapore, Cordlife was the first private cord blood bank to release cord blood units for the treatment of cerebral palsy.

Cordlife’s track record has won the Group many accolades and awards, including: Best Medical Service Award 2010 by Capital CEO Supreme Brand Awards; Top Pregnant/Baby Products Award 2011 by Pregnancy Magazine; Outstanding Financial Strength Cord Blood Bank 2012 by Quamnet Outstanding Enterprise Awards; Most Popular Brand Award 2010 – The Most Popular Cord Blood Bank by TVB Weekly; and U-Choice Lifestyle Brand Award 2010 by Metroinfo FM99.7. In October 2012, Cordlife was awarded the prestigious SIAS Investors’ Choice Awards as runner-up in the “Most Transparent Company Award 2012” New Issues Category.

ABOUT THOMSON MEDICAL PTE. LTD.

Incorporated in 1977, Thomson Medical is one of Singapore’s leading providers of healthcare services for women and children. It owns and operates Thomson Medical Centre, a fully integrated hospital that provides a comprehensive range of facilities and services with focus in obstetrics and gynaecology (O&G) and paediatric services.

Thomson Medical has grown its operations which now include a network of Thomson Women’s Clinics island-wide and other subsidiary companies such as Thomson Specialist Skin Centre, Thomson Dental Centre, Thomson Fertility Centre, Thomson Lifestyle Centre, Thomson Women Cancer Centre, Thomson Paediatric Centre and Thomson Chinese Medicine.

3 Awarded to Cordlife Hong Kong
Thomson Medical has won numerous awards and accolades over the years. Notably, it is the first company to be inducted into the Singapore Prestige Brand Award (“SPBA”) Hall of Fame, being a six-time consecutive winner of SPBA from 2004 to 2009. Demonstrating service excellence, Thomson Medical topped the healthcare sector in the Customer Satisfaction Index for Singapore (CSISG) in 2010 and 2011.

For more information, please visit Thomson Medical’s corporate website at thomsonmedical.com.

ISSUED ON BEHALF OF : Cordlife Group Limited
BY : Citigate Dewe Rogerson, i.MAGE Pte Ltd
55 Market Street
#02-01
SINGAPORE 048941

CONTACT : Ms Dolores Phua / Ms Chelsea Phua
DURING OFFICE HOURS : 6534-5122 (Office)
AFTER OFFICE HOURS : 9750-8237 / 9667-5837 (Handphone)
EMAIL : dolores.phua@citigatedrimage.com / chelsea.phua@citigatedrimage.com

046/13/004/CGL
May 9, 2013